Clearsight Advises Ambit in its Acquisition by Danforth Health

WASHINGTON, Sept. 9, 2026 /PRNewswire/ -- Clearsight Advisors, Inc. ("Clearsight") is pleased to announce a successful transaction in its Healthcare and Life Sciences Services practice. Clearsight served as the exclusive sell-side advisor to Ambit RD, Inc. (the "Company" or "Ambit") on its acquisition by Danforth Health, Inc. ("Danforth"), a portfolio company of Avesi Partners ("Avesi").

Ambit is a leading technology-enabled solutions company focused on serving rare and specialty biopharma markets. The Company specializes in commercial strategy, advanced analytics, and patient identification solutions that help biopharmaceutical organizations improve patient finding, accelerate therapy adoption, and enhance patient outcomes. Through a combination of data-driven consulting, proprietary technology, and deep commercial expertise, Ambit helps stakeholders across the clinical and commercial continuum address challenges related to patient identification, diagnosis, healthcare provider engagement, and therapy activation. Supported by its Strategic Services, Analytics & Data Services, and Patient ID Services offerings, the Company has established itself as a trusted partner to life sciences organizations seeking to bring life-changing therapies to patients with rare and specialty conditions.

Danforth Health, a portfolio company of Avesi Partners, is a leading provider of business, clinical, and commercial solutions to life sciences companies. Through its integrated platform, Danforth helps clients navigate key stages of the product lifecycle, from development through commercialization. Supported by Avesi's investment and operational expertise, Danforth continues to expand its capabilities through strategic acquisitions that enhance its service offerings across the life sciences ecosystem.

Through this partnership, Ambit is well positioned to accelerate its next phase of growth and further strengthen its role as a trusted partner to rare and specialty biopharma organizations. The combination enhances Ambit's ability to deliver commercial strategy, advanced analytics, patient identification, and technology-enabled solutions while benefiting from Danforth's broader business, clinical, and commercial platform. Together, the organizations are expected to provide more comprehensive support across the product lifecycle and continue investing in capabilities that help clients improve patient outcomes.

Ned Kitfield, Co-Founder and Chief Commercial Officer of Ambit, commented, "This partnership represents an exciting opportunity to expand the value we deliver to life sciences organizations serving rare and specialty disease populations. By combining Ambit's expertise in commercial strategy, advanced analytics, patient identification, and technology-enabled solutions with Danforth's broader platform, we are well positioned to enhance our capabilities, accelerate innovation, and better support our clients across the product lifecycle."

Rob Sederman, Co-Founder and Chief Executive Officer of Ambit, added, "As we evaluated opportunities to support Ambit's continued growth, it was important to find a partner that shared our vision for helping life sciences organizations better serve patients with rare and specialty diseases. Clearsight's life sciences services experience, thoughtful advice, and execution support helped us achieve an excellent outcome. We are excited to partner with Danforth and begin this next chapter together."

Tory Steel, Managing Director at Clearsight Advisors, commented, "Ambit has established itself as a highly respected partner within the rare and specialty disease market. The Company's combination of consulting expertise, analytics capabilities, and patient-focused solutions has created a differentiated platform that delivers meaningful value to clients. We believe Ambit is exceptionally well positioned for continued growth within the Danforth platform."

Austin Kuhn, Director at Clearsight Advisors, added, "This transaction reflects broader demand across the life sciences ecosystem for specialized partners that can help organizations navigate increasingly complex commercialization and patient engagement challenges. Ambit's capabilities complement Danforth's existing service offerings and further strengthen the combined platform's ability to support life sciences clients across critical stages of growth."

The Clearsight deal team included Tory Steel, Greg Treger, Austin Kuhn, Jake Kohlbrenner, Grace Bryant, and William Trukenbrod.

About Clearsight Advisors

Clearsight Advisors is an investment banking firm dedicated to providing world-class M&A and capital-raising solutions to growth-oriented Business Services and Technology companies. Clearsight Advisors, Inc. is a wholly owned subsidiary of Regions Financial Corporation. No offerings of securities are made through this site; all securities are offered exclusively through RF M&A Services LLC, a registered broker-dealer and member of FINRA and SIPC. Testimonials may not be representative of all client experiences. Testimonials are not a guarantee of future performance or success. Links to external sites are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by Clearsight Advisors of any of the products, services or opinions of the corporation or organization or individual. Clearsight Advisors is not responsible for the accuracy or content of linked third-party websites. Also, please be aware that the security and privacy policies on these third-party sites may differ from our policies, so please read third-party privacy and security policies closely. For more information visit https://www.clearsightadvisors.com

SOURCE Clearsight Advisors